Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Higher skeletal muscle mass is associated with higher blood pressure and left ventricular mass.

Journal of hypertension·2026
Same author

Prevention of heart failure.

European heart journal·2026
Same author

Management and long-term surveillance of hypertensive disorders of pregnancy.

Nature reviews. Cardiology·2026
Same author

Climate Change and Cardiovascular Risk Factors Management: Emerging Challenges and Strategies for Prevention and Adaptation.

European journal of preventive cardiology·2026
Same author

Guidelines are not enough: primary cardiovascular prevention starts in primary care.

European journal of preventive cardiology·2026
Same author

Model-based cost-effectiveness analysis of first-line pharmacotherapy combinations in adults with chronic heart failure and reduced ejection fraction.

Heart (British Cardiac Society)·2026
Same journal

Prosthetic valve thrombosis: contemporary concepts in diagnosis and management.

Expert review of cardiovascular therapy·2026
Same journal

Life's essential 8 and its role in cardiovascular health: evolution, evidence, and future directions.

Expert review of cardiovascular therapy·2026
Same journal

Efficacy and safety of clopidogrel and aspirin initiated within 72 hours after mild ischemic stroke or high-risk TIA by sex: a prespecified subgroup analysis of the INSPIRES trial.

Expert review of cardiovascular therapy·2026
Same journal

Approaches to transcatheter aortic valve replacement failure: is more focus on prevention required?

Expert review of cardiovascular therapy·2026
Same journal

Vericiguat for heart failure with reduced ejection fraction: a perspective from approval to real-world clinical treatment.

Expert review of cardiovascular therapy·2026
Same journal

Early autonomic neuropathy in prediabetes: an overlooked driver of cardiometabolic risk.

Expert review of cardiovascular therapy·2026
See all related articles

Related Experiment Video

Updated: Jun 22, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Fondaparinux: an overview.

Sunil K Nadar1, Deepak Goyal, Eduard Shantsila

  • 1Specialist Registrar, Department of Cardiology, University Hospital of Coventry and Warwickshire, Clifford Bridge Road, Coventry, CV2 2DX, UK.

Expert Review of Cardiovascular Therapy
|June 10, 2009
PubMed
Summary
This summary is machine-generated.

Fondaparinux, a synthetic anticoagulant, effectively prevents and treats venous thromboembolism and pulmonary embolism. It shows comparable efficacy to other anticoagulants with a lower bleeding risk in acute coronary syndromes.

More Related Videos

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Jun 22, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Area of Science:

  • Pharmacology
  • Hematology
  • Cardiology

Background:

  • Fondaparinux is a synthetic pentasaccharide anticoagulant.
  • It selectively inhibits Factor Xa, a key enzyme in thrombin formation.
  • Its predictable pharmacokinetic profile eliminates the need for platelet monitoring.

Purpose of the Study:

  • To review the efficacy and safety of fondaparinux in various clinical settings.
  • To compare fondaparinux with other anticoagulants like enoxaparin and unfractionated heparin.
  • To evaluate fondaparinux's role in venous thromboembolism, pulmonary embolism, and acute coronary syndromes.

Main Methods:

  • Review of current evidence and clinical studies.
  • Comparative analysis of fondaparinux against enoxaparin and unfractionated heparin.
  • Assessment of outcomes including efficacy, safety, and bleeding complications.

Main Results:

  • Fondaparinux is as effective, or more so, than enoxaparin in preventing postoperative venous thromboembolism.
  • It demonstrates similar effectiveness to enoxaparin and unfractionated heparin in treating venous and pulmonary embolism.
  • In acute coronary syndromes, fondaparinux is non-inferior to enoxaparin for major cardiac outcomes with reduced bleeding, except for primary PCI where heparin is preferred.

Conclusions:

  • Fondaparinux is a valuable anticoagulant for venous thromboembolism and pulmonary embolism.
  • It offers a favorable safety profile, particularly reduced bleeding risk, in acute coronary syndromes.
  • Fondaparinux's role in ST-elevation myocardial infarction requires careful consideration, with unfractionated heparin preferred for primary PCI.